Result card

  • ECO7: To what extent can differences in costs, outcomes, or ‘cost effectiveness’ be explained by variations between any subgroups using IGG and its comparator(s)?
English

To what extent can differences in costs, outcomes, or ‘cost effectiveness’ be explained by variations between any subgroups using IGG and its comparator(s)?

Authors: Anna-Theresa Renner, Neill Booth, Esther Kraft, Ingrid Rosian-Schikuta, Matthias Schwenkglenks

Internal reviewers: Pseudo297 Pseudo297

Given the lack of available data and lack of published evidence on the efficacy and/or the effectiveness of the intervention, the researchers (and internal reviewers) of this ‘Costs and economic evaluation’ domain agreed that it would not be prudent to undertake research into costs or undertake an economic evaluation.

Renner A et al. Result Card ECO7 In: Renner A et al. Costs and economic evaluation In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267